SCHEMBL3414852

SCHEMBL3414852

B[C@H]1CC[C@@](C)(CO)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20434443 0.83
SCHEMBL21264897 0.80
SCHEMBL12899559 0.76
SCHEMBL11410719 0.76
SCHEMBL21972024 0.75
SCHEMBL25881700 0.74 F10 (0.30)
SCHEMBL12060944 0.73
SCHEMBL23374138 0.72 KDM4E (0.30)
SCHEMBL10149500 0.72 KDM4E (0.30)
SCHEMBL280523 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158779-B2 Antiviral nucleosides MEDIVIR AB (SE) 2012-04-17 US disclosed
US-20110172410-A1 ANTIVIRAL NUCLEOSIDES MEDIVIR AB (SE) 2011-07-14 US disclosed
WO-2011067195-A1 BIOMARKERS FOR PREDICTING SUSTAINED RESPONSE TO HCV TREATMENT F. HOFFMANN-LA ROCHE AG (CH) 2011-06-09 WO disclosed
WO-2011058084-A1 BIOMARKERS FOR PREDICTING RAPID RESPONSE TO HCV TREATMENT F. HOFFMANN-LA ROCHE AG (CH) 2011-05-19 WO disclosed
US-7935681-B2 Antiviral nucleosides MEDIVIR AB (SE) 2011-05-03 US disclosed
US-20110015148-A1 ANTIVIRAL NUCLEOSIDES MEDIVIR AB (SE) 2011-01-20 US disclosed
WO-2010069809-A1 BIOMARKERS FOR HCV TREATMENT RESPONSE F. HOFFMANN-LA ROCHE AG (CH) 2010-06-24 WO disclosed
WO-2008043704-A1 HCV NUCLEOSIDE INHIBITOR MEDIVIR AB (SE) 2008-04-17 WO disclosed
WO-2007065829-A1 ANTIVIRAL NUCLEOSIDES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-14 WO disclosed